Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease (NAFLD), also known as hepatic steatosis, is a condition where more than 5% of the liver's weight is composed of excess fat unrelated to alcohol consumption, often presenting with few or no symptoms but potentially leading to serious complications such as cirrhosis, liver cancer, and esophageal varices.
Health Outcomes
- Activation of Nrf2 Pathway
- Aggravated Liver Injury
- Alleviated Intestinal Metabolic Disorders
- Alleviated Liver Injury
- Alleviated Non-Alcoholic Fatty Liver Disease
- Alleviated Organ Injury
- Altered Amino Acid Metabolism
- Altered Bile Acid Composition
- Altered Bile Acid Metabolism
- Altered Circulating Metabolic Profile
- Altered Dominant Microbial Community
- Altered Fatty Acid Profile in Offspring
- Altered Fatty Acid Profiles
- Altered Fecal Butyrate Levels
- Altered Fecal Metabolite Levels
- Altered Metabolic Profile
- Altered Metabolite Profile
- Altered Plasma Metabolite Levels
- Altered Short-Chain Fatty Acid Production by Gut Microbiota
- Atherogenic Lipid Profile
- Attenuated Hepatic Disorders
- Change in Waist-to-Hip Ratio
- Changed Albumin Level
- Changed Plasma Glycerophospholipid Levels
- Changes in Health Status from Probiotic Intervention
- Changes in Liver Fibrosis Markers
- Characterized Carbohydrate Metabolism Enzyme Activity
- Decreased HDL Cholesterol Level
- Degraded Non-Digestible Carbohydrates
- Distinct Metabolic Profile
- Elevated Acetic Acid Levels
- Elevated Alkaline Phosphatase Levels
- Elevated Bile Acid Levels
- Elevated Hepatic Enzyme Levels
- Elevated Interleukin-6 Levels
- Elevated Malondialdehyde Levels
- Elevated Plasma Glycerol Levels
- Elevated Plasma-Branched Chain Amino Acids
- Elevated Redox Status
- Elevated Serum Alanine Aminotransferase Levels
- Elevated Serum Aspartate Aminotransferase Levels
- Elevated Serum Enzyme Levels
- Elevated Serum Leptin Levels
- Elevated Triglyceride Levels
- Enhanced AMPK Activation
- Enhanced Active Metabolite Levels
- Enhanced Antioxidant Metabolism
- Enhanced Antioxidative Capacity
- Enhanced Beneficial Gut Microbiota
- Enhanced Bile Salt Resistance
- Enhanced Endoplasmic Reticulum Stress Response
- Enhanced Fatty Acid Metabolism
- Enhanced Gut Microbiota
- Enhanced Hepatic Fatty Acid Oxidation
- Enhanced Hepatic Peroxisomal Beta Oxidation
- Enhanced Lipid Metabolism in Adipose Tissue
- Enhanced Liver Protection
- Enhanced Metabolic Function
- Enhanced Metabolic Pathway Activation
- Enhanced Metabolite Levels
- Improved Antioxidant Activity
- Improved Antioxidative Capacity
- Improved Antioxidative Enzyme Activities
- Improved Bile Acid Metabolism
- Improved Bioactivity
- Improved Biochemical Parameters
- Improved Blood Biochemical Parameter
- Improved Blood Biochemistry
- Improved Blood Chemistry
- Improved Blood Clinical Chemistry
- Improved Blood Lipid Profile
- Improved Body Mass Index
- Improved CST Status to CST I
- Improved Carbohydrate Metabolism
- Improved Child-Pugh Score
- Improved Child-Pugh Scores
- Improved Cholesterol Levels
- Improved Cholesterol Metabolism
- Improved Cholesterol Profile
- Improved Cholesterol Regulation
- Improved Detoxification
- Improved Dyslipidemia
- Improved Effectiveness in Nonalcoholic Steatohepatitis
- Improved Endotoxemia-related Inflammation
- Improved Energy Metabolism in White Adipose Tissue
- Improved Enzyme Levels (ADH, ALDH)
- Improved FGF21 Sensitivity
- Improved Fatty Acid Composition
- Improved Fatty Acid Oxidation
- Improved Fatty Acid Profile
- Improved Fibrosis
- Improved Glutathione Redox Ratio
- Improved Glycerophospholipid Metabolism
- Improved Gut Microbiome Function
- Improved Gut Microbiota Diversity
- Improved Gut Microbiota-Related Pathways
- Improved HOMA Index
- Improved Hepatic Cholesterol Homeostasis
- Improved Hepatic Damage
- Improved Hepatic Disease
- Improved Hepatic Function
- Improved Hepatic Insulin Sensitivity
- Improved Hepatic Oxidative Stress
- Improved Hepatic Steatosis Severity
- Improved Hepatopancreas Health
- Improved Incretin Release
- Improved Insulin Resistance
- Improved Insulin Sensitivity
- Improved Lipid Levels
- Improved Lipid Metabolism
- Improved Lipid Profile
- Improved Lipid Serum Homeostasis
- Improved Liver Antioxidant Capacity
- Improved Liver Biomarkers
- Improved Liver Disease Biomarkers
- Improved Liver Enzyme Activity
- Improved Liver Enzyme Function
- Improved Liver Fatty Acid Composition
- Improved Liver Function
- Improved Liver Function (γ-glutamyltranspeptidase)
- Improved Liver Health
- Improved Liver Histology
- Improved Liver Lipid Deposition
- Improved Liver Metabolic Pathways
- Improved Liver Morphology
- Improved Liver Regeneration
- Improved Liver Steatosis
- Improved MASH Resolution
- Improved Metabolic Activity of Bacillus coagulans
- Improved Metabolic Disease Markers
- Improved Metabolic Disorders
- Improved Metabolic Function
- Improved Metabolic Health
- Improved Metabolic Homeostasis
- Improved Metabolic Parameters
- Improved Metabolic Pathway Functions in Intestinal Microbiota
- Improved Metabolic Profile
- Improved Metabolic Regulation
- Improved Metabolic Syndrome Biomarkers
- Improved Metabolism
- Improved Metabolism of Host-Derived Glycans
- Improved Metabolome Profile
- Improved Microbial Metabolism Regulation
- Improved Minimal Hepatic Encephalopathy
- Improved Nutritional Metabolism
- Improved Obesity Metrics
- Improved Obesity Parameters
- Improved Organ Histology
- Improved Oxidative Metabolism Regulation
- Improved Oxidative Stress Biomarker
- Improved Plasma Lipid Levels
- Improved Prognosis of Type 2 Diabetes Mellitus
- Improved Protein Synthesis in Liver
- Improved Redox Homeostasis
- Improved Serum Antioxidant Capacity
- Improved Serum Biochemical Catalase Levels
- Improved Serum Biochemistry
- Improved Serum Biomarkers
- Improved Serum Hyaluronan Levels
- Improved Serum Parameters
- Improved Superoxide Dismutase Activity
- Improved Superoxide Dismutase Level
- Improved Systemic Health
- Improved Systemic Metabolism
- Improved Total Cholesterol Levels
- Improved Triglyceride Levels
- Improved VLDL Cholesterol
- Improved Waist-to-Hip Ratio
- Improved Weight Management
- Improved n-6 to n-3 PUFA Ratio
- Increased AMPK Activation
- Increased Adiponectin Levels
- Increased Antioxidant Levels
- Increased Aspartate Aminotransferase Concentration
- Increased Aspartate Aminotransferase Level
- Increased Aspartate Transferase Level
- Increased Autophagy
- Increased Betaine Content
- Increased Bioactivity
- Increased Body Mass Index
- Increased Body Weight
- Increased Body Weight Gain
- Increased Branched Chain Amino Acid Levels
- Increased Branched-Chain Fatty Acids Concentration
- Increased CD163+ Macrophage Density
- Increased CD68+ Macrophage Density
- Increased CPT1 Protein Levels
- Increased Catalase Levels
- Increased Cell Adhesion
- Increased Cellular Apoptosis
- Increased Cholesterol Excretion
- Increased Circulating Bile Acid Levels
- Increased Clinically Meaningful Collagen Synthesis
- Increased Degradation of Non-Assimilated Compounds
- Increased Dicarboxylic Fatty Acid Level
- Increased ER Stress-Associated Proteins
- Increased Enzyme Production
- Increased Expression of Oxidation-Related Gene
- Increased FNDC5 Concentration
- Increased Fasting Insulin Level
- Increased Fatty Acid Oxidation
- Increased Fecal Triglyceride Levels
- Increased Free Fatty Acid Levels
- Increased GLP-1 Levels
- Increased GSH/GSSG Ratio
- Increased Glucagon-Like Peptide 1 Level
- Increased Glycine Level
- Increased Hepatic Antioxidant Enzyme Activity
- Increased Hepatic Antioxidant Enzyme Levels
- Increased Hepatic Glutathione Content
- Increased Hepatic Glutathione Levels
- Increased Hepatic Lipid Metabolism Markers
- Increased Histological Damage
- Increased Hydroxy Fatty Acid Level
- Increased IPA Levels
- Increased Inhibition of Lipid Oxidation
- Increased Insulin Level
- Increased Insulin Resistance Level
- Increased Insulin Secretion
- Increased Lipid Oxidation
- Increased Liver Enzyme Levels
- Increased Malondialdehyde Levels
- Increased Muscle Fat Content
- Increased NRF2 Levels
- Increased Nitrogen Degradation Postprandially
- Increased Nrf2 Protein Content
- Increased Organ Weights
- Increased Oxidative Stress
- Increased PPAR-γ Activity
- Increased Plasma ApoA-V Levels
- Increased Plasma Deconjugated Bile Acids
- Increased Polyphenol Level
- Increased Polyunsaturated Fatty Acids in Breast Meat
- Increased Portal Endotoxin Levels
- Increased Production of Acetate
- Increased Propionate Production
- Increased Rikenellaceae Abundance
- Increased SCFA Concentration
- Increased SCFA Levels
- Increased SCFA Production
- Increased SCFA-Producing Bacteria
- Increased Serum Antioxidant Levels
- Increased Serum Free Fatty Acid Levels
- Increased Serum Peroxidase Activity
- Increased Serum Protein Levels
- Increased Serum Total Bile Acid Levels
- Increased Serum Triglycerides
- Increased Serum Tumor Necrosis Factor-α Levels
- Increased Short-Chain Fatty Acid Production
- Increased Short-Chain Fatty Acid-Producing Microbial Population
- Increased Short-Chain Fatty Acid-Producing Microbial Taxa
- Increased Short-Chain Fatty Acids Concentrations
- Increased Solid Non-Fat Content
- Increased Thermoplasma Abundance
- Increased Total Bile Acid Levels
- Increased Total Bile Acids
- Increased Total Body Iron Level
- Increased Triglyceride Level
- Increased Uncoupling Protein 2 Expression
- Increased Uncoupling Protein 2 Level
- Increased Visceral Fat Mass
- Increased c9t11 CLA Production in Adipose Tissue
- Induction of Browning of White Adipose Tissue
- Influence on Metabolic Pathways
- Inhibited Absorption of Advanced Glycation End-products (AGEs)
- Inhibited Activation of Apoptotic Biomarkers
- Inhibited Lipid Oxidation
- Liver Histopathological Damage
- Lowered Serum Levels of Liver Injury Markers
- Maintained Albumin Levels
- Maintained Cell Viability in Low pH
- Maintained Metabolic Homeostasis
- Maintained Normal ALT Levels
- Maintained Normal Liver Function
- Maintained Safety with Repeated Oral Exposure
- Mature Gut Microbiota
- Microbiome Remodeling
- Modified Hepatic Inflammatory Cell Pattern
- Modified Serum Metabolomic Pathways
- Modulated Bile Acid Profile in Ileum
- Modulated Diurnal Short-Chain Fatty Acid Production
- Modulated Gut Microbiome Composition
- Modulated Gut Microbiota
- Modulated Liver Metabolic Pathways
- Modulated Metabolite Profile
- Modulated PPAR/SREBP Pathway
- Multiple Health-Promoting Effects
- Neutralized Reactive Oxygen Species
- No Change in Ectopic Fat Content
- No Change in Fibrosis
- No Change in HDL Cholesterol
- No Change in Metabolic Health
- No Significant Change in Aflatoxin Distribution or Metabolism
- Normalization of Blood Biochemical Parameters
- Normalized Gut Metabolites
- Normalized Lipid Metabolism
- Potential Modulation of FGF-19 Levels
- Preserved Liver Function
- Preserved Liver Structure
- Prevented Increase in Total Bilirubin
- Prevented Liver Fibrosis
- Prevented Liver Injury
- Prevented Liver Pathway Dysregulation
- Prevention of Liver Steatosis
- Prevention of Nonalcoholic Fatty Liver Disease
- Prevention of Obesity Transition
- Reduced AFB1-Induced Liver Damage
- Reduced ALT Levels
- Reduced AST Levels
- Reduced Abdominal Adiposity
- Reduced Abdominal Fat
- Reduced Abdominal Visceral Fat
- Reduced Abnormal Increase in Bilirubin
- Reduced Absorption of AFB1
- Reduced Abundance of Odoribacter
- Reduced Acetate to Propionate Ratio
- Reduced Acute Liver Injury
- Reduced Adipocyte Hypertrophy
- Reduced Adipocyte Senescence
- Reduced Adverse Physiometabolic Effects
- Reduced Alanine Transaminase Activity
- Reduced Alanine Transaminase Levels
- Reduced Aminotransferase Levels
- Reduced Ammonia Excretion
- Reduced Ammonia Levels
- Reduced Anticoagulation / Increased Warfarin Variability
- Reduced Aspartate Aminotransferase to Alanine Aminotransferase Ratio
- Reduced Aspartate Transaminase Activity
- Reduced Biochemical Marker Levels
- Reduced Blood Ammonia Level
- Reduced Blood Lipid Levels
- Reduced Carboxymethyl Lysine
- Reduced Catalase Activity
- Reduced Cellular Senescence
- Reduced Cholesterol Metabolism
- Reduced Circulating Endotoxin
- Reduced Clostridium Cluster IV Content
- Reduced De Novo Lipogenesis
- Reduced Dimethyl Sulfide Level
- Reduced Dyslipidemia Parameters
- Reduced Dyslipidemia in Metabolic Syndrome
- Reduced Elevated Liver Enzymes
- Reduced Elevated Serum Alanine Aminotransferase (ALT)
- Reduced Endoplasmic Reticulum Stress Markers
- Reduced Endotoxin Levels
- Reduced Epididymal Fat Tissue Accumulation
- Reduced Fasting Insulin Level
- Reduced Fat Gain
- Reduced Fatty Acid Synthesis
- Reduced Fatty Infiltration in Hepatocytes
- Reduced Fecal Bile Acid Levels
- Reduced Fecal Secondary Bile Acid Contents
- Reduced Fibrosis Marker Levels
- Reduced Flavonoid Levels
- Reduced Fumonisin B1 Levels
- Reduced GLP-1 Levels
- Reduced GPT Level
- Reduced Gemmiger formicilis Abundance
- Reduced Glucuronide Metabolite Level
- Reduced Glycation End Product Accumulation
- Reduced HDL Levels
- Reduced HIF-1α Level
- Reduced HOMA-IR
- Reduced Harmful Enzyme Activity
- Reduced Harmful Lipid Levels
- Reduced Hepatic Apoptosis
- Reduced Hepatic CML Absorption
- Reduced Hepatic Cholesterol
- Reduced Hepatic Damage Indices
- Reduced Hepatic Fat Accumulation
- Reduced Hepatic Glycogen Levels
- Reduced Hepatic Histological Injury
- Reduced Hepatic Inflammation
- Reduced Hepatic Inflammation Markers
- Reduced Hepatic Inflammation and Oxidative Stress
- Reduced Hepatic Inflammatory Cytokines
- Reduced Hepatic Insulin Resistance
- Reduced Hepatic Lipid Accumulation
- Reduced Hepatic Lipid Levels
- Reduced Hepatic Lipid Synthesis
- Reduced Hepatic Lipogenesis
- Reduced Hepatic Neutral Lipids
- Reduced Hepatic Nitric Oxide Production
- Reduced Hepatic Oxidative Stress
- Reduced Hepatic Steatosis
- Reduced Hepatic Steatosis Severity
- Reduced Hepatic Stellate Cell Activation
- Reduced Hepatic Triglyceride Levels
- Reduced Hepatic Xanthine Oxidase Activity
- Reduced Hepatocellular Carcinoma Progression
- Reduced Hepatocellular Carcinoma Recurrence
- Reduced Hepatocellular Damage
- Reduced Hepatocyte Ballooning
- Reduced Hepatocyte Necrosis
- Reduced Hepatocyte Oxidative Stress
- Reduced Hepatotoxicity
- Reduced Hepatotoxicity from Iron Oxide Nanoparticles
- Reduced High-Density Lipoprotein (HDL) Cholesterol
- Reduced Histological Damage
- Reduced Histological Damage Scores
- Reduced Histological Liver Injury
- Reduced Histological Scores
- Reduced Homeostatic Model Assessment for Insulin Resistance
- Reduced Hypercholesterolemia
- Reduced Immune Cell Proliferation
- Reduced Incidence of Liver Cancer
- Reduced Inflammation in Adipose Tissue
- Reduced Insulin Response
- Reduced Insulin Sensitivity
- Reduced Insulin/IGF-1 Signaling
- Reduced Intracellular Triglyceride Levels
- Reduced LDL Cholesterol
- Reduced Lathosterol to Total Cholesterol Ratio
- Reduced Lipid Deposition
- Reduced Lipid Oxidation
- Reduced Lipid Peroxidation
- Reduced Lipid Profiles
- Reduced Lipid Synthesis
- Reduced Lipid Synthesis Enzyme Levels
- Reduced Lipopolysaccharide-Binding Protein
- Reduced Liver Biochemical Markers
- Reduced Liver Cholesterol
- Reduced Liver Cholesterol Content
- Reduced Liver Cholesterol Levels
- Reduced Liver Damage
- Reduced Liver Damage Indicators
- Reduced Liver Damage Markers Levels
- Reduced Liver Disease Progression
- Reduced Liver Disease Symptoms
- Reduced Liver Enzyme Activity
- Reduced Liver Enzyme Levels
- Reduced Liver Fat
- Reduced Liver Fat Accumulation
- Reduced Liver Fat Content
- Reduced Liver Fat Deposition
- Reduced Liver Fat Formation
- Reduced Liver Fat Vacuoles
- Reduced Liver Fat Vacuolization
- Reduced Liver Fibrosis
- Reduced Liver Function
- Reduced Liver Function Indicators
- Reduced Liver Inflammation
- Reduced Liver Inflammation Fibrosis Score
- Reduced Liver Injury
- Reduced Liver Injury Indicators
- Reduced Liver Injury Marker
- Reduced Liver Lesion Severity
- Reduced Liver Lipid Accumulation
- Reduced Liver Lipid Content
- Reduced Liver Oxidative Damage
- Reduced Liver Oxidative Stress Injury
- Reduced Liver Stiffness
- Reduced Liver Total Cholesterol
- Reduced Liver Toxicity
- Reduced Liver Triglyceride Content
- Reduced Liver Triglycerides
- Reduced Liver Weight-to-Body Weight Ratio
- Reduced Lysophosphatidylethanolamine 18:1 Level
- Reduced Malondialdehyde Generation
- Reduced Malondialdehyde Level
- Reduced Mesenteric Adipose Tissue Accumulation
- Reduced Metabolic Disease Risk
- Reduced Metabolic Disorders Incidence
- Reduced Metabolic Dysregulation
- Reduced Metabolic Endotoxemia
- Reduced Metabolic Function
- Reduced Metabolic Inflammation
- Reduced Metabolic Lipopolysaccharide-Related Inflammation
- Reduced Metabolic Syndrome
- Reduced Microbial Richness
- Reduced Microbial Translocation to the Liver
- Reduced NAFLD Activity Score
- Reduced NASH Activity
- Reduced NASH Activity Index
- Reduced Non-Communicable Disease Risk
- Reduced Obesity-Related Microbial Taxa
- Reduced Obesity-Related Taxa
- Reduced Oleic Acid-Induced Triglyceride Accumulation
- Reduced Organ Damage
- Reduced Organ Injury
- Reduced Organ Weight
- Reduced Oxidative Stress
- Reduced Oxidative Stress Marker Level
- Reduced Pathological Changes of Liver
- Reduced Plasma Endotoxin Concentration
- Reduced Plasma Lipopolysaccharide Levels
- Reduced Plasma Non-Esterified Fatty Acid Concentrations
- Reduced Plasma Triglycerides
- Reduced Portal Vein LPS Levels
- Reduced Post-Exercise Serum Amyloid A Increase
- Reduced Postprandial Insulin
- Reduced Postprandial Triacylglycerol Response
- Reduced Procollagen Type 1 N-terminal Propeptide Level
- Reduced Proinflammatory Bacteria
- Reduced SCD1 Activity
- Reduced Salmonella Translocation to Liver
- Reduced Saturated Fatty Acids in Breast Meat
- Reduced Senescence-Associated Secretory Phenotype
- Reduced Serum 8-isoprostane Concentrations
- Reduced Serum Alanine Aminotransferase Activity
- Reduced Serum Alanine Aminotransferase Levels
- Reduced Serum Gamma Glutamine Transaminase Levels
- Reduced Serum Glycerophospholipid Levels
- Reduced Serum Lipid Levels
- Reduced Serum Transaminase Levels
- Reduced Serum Triacylglycerols
- Reduced Serum Triglycerides
- Reduced Short-Chain Fatty Acid Levels in Feces
- Reduced Short-Chain Fatty Acids (SCFA)
- Reduced Steatohepatitis
- Reduced Steatosis
- Reduced Steatosis Score
- Reduced Stigmasterol Absorption
- Reduced Stigmasterol Level
- Reduced Succinate Levels
- Reduced Sugar-Sweetened Beverage Intake
- Reduced Symptoms Associated with High-Fat Diet
- Reduced Symptoms of High-Fat Diet Pathologies
- Reduced Systemic Endotoxemia at Rest
- Reduced TMAO Levels
- Reduced Thiobarbituric Acid-Reactive Substance Levels
- Reduced Total Blood Cholesterol
- Reduced Total Cholesterol Levels
- Reduced Triglyceride Levels
- Reduced Triglyceridemia
- Reduced Triglycerides
- Reduced Type 2 Diabetes Symptoms
- Reduced Very Low-Density Lipoprotein
- Reduced Visceral Fat
- Reduced Visceral Fat Accumulation
- Reduced Visceral Fat Area
- Reduced Visceral Fat Mass
- Reduced Waist Circumference
- Reduced Waist-to-Height Ratio
- Regenerated Hepatic Tissue
- Regulated Blood Lipid Levels
- Regulated Gut Microbiota Metabolic Function
- Regulated Lipid Metabolism
- Regulated Lipid Metabolism in Epididymal Fat Pads
- Regulated Liver Glycerophospholipid Metabolism
- Regulated Liver Metabolite Levels
- Regulated Metabolic Function
- Regulated Microbial Metabolism
- Remodeled Intestinal Microbiota
- Restored Lipid Metabolism
- Restored Short-Chain Fatty Acid Levels
- Reversed Microbiome Metabolic Changes
- Significant Histopathological Changes in Liver
- Stabilized Total Bilirubin Levels
- Stabilized Visceral Fat Area
- Stable Alanine Aminotransferase Levels
- Stable Aspartate Aminotransferase Levels
- Stable Fecal Deconjugated Bile Acid Levels
- Stable High-Density Lipoprotein Cholesterol Level
- Stable Organ Weight
- Suppressed PPAR/SREBP Pathway Gene Activity
- Suppressed Wnt/β-catenin Signaling
- Unchanged Blood Parameters
- Unchanged Insulin Sensitivity
- Unchanged Total Cholesterol